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Indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) are tryptophan-
degrading enzymes that have independently evolved to catalyze the first step in tryptophan
catabolism via the kynurenine pathway (KP). The depletion of tryptophan and formation of
KP metabolites modulates the activity of the mammalian immune, reproductive, and cen-
tral nervous systems. IDO and TDO enzymes can have overlapping or distinct functions
depending on their expression patterns.The expression ofTDO and IDO enzymes in mam-
mals differs not only by tissue/cellular localization but also by their induction by distinct
stimuli. To add to the complexity, these genes also have undergone duplications in some
organisms leading to multiple isoforms of IDO or TDO. For example, many vertebrates,
including all mammals, have acquired two IDO genes via gene duplication, although the
IDO1-like gene has been lost in some lower vertebrate lineages. Gene duplications can
allow the homologs to diverge and acquire different properties to the original gene. There
is evidence for IDO enzymes having differing enzymatic characteristics, signaling proper-
ties, and biological functions. This review analyzes the evolutionary convergence of IDO
andTDO enzymes as tryptophan-catabolizing enzymes and the divergent evolution of IDO
homologs to generate an enzyme family with diverse characteristics not possessed by
TDO enzymes, with an emphasis on the immune system.
Keywords: convergent evolution, divergent evolution, indoleamine 2,3-dioxygenase, tryptophan 2,3-dioxygenase,
gene duplication, immunoregulation
EVOLUTION OF TRYPTOPHAN-CATABOLIZING ENZYMES
The concepts of convergent and divergent evolution can apply
to multi-cellular organisms or at the level of gene families, such
as those that encode a particular enzymatic activity [reviewed
in Ref. (1)]. In the first case, distinct enzyme superfamilies can
evolve to catalyze the same reaction, i.e., functional convergence.
Second, sequence divergence within families of enzymes can lead
to functional divergence of enzyme homologs. In this review, we
bring together and analyze evidence, mostly gathered in the last
decade, which shows that the enzymes catalyzing the first step in
the kynurenine pathway (KP) are a fascinating example of both
these processes (Figure 1). The two enzymes, tryptophan 2,3-
dioxygenase (TDO) and indoleamine 2,3-dioxygnease (IDO), are
structurally distinct proteins that nonetheless have evolved to cat-
alyze the same reaction, the conversion of tryptophan (Trp) to
N -formylkynurenine. The result of TDO and IDO activity is the
depletion of Trp and production of metabolites of the KP. For
mammals, Trp is an essential amino acid with most dietary Trp
being metabolized through the KP (2). Some Trp is also required
for synthesis of protein and the neurochemical serotonin. Activity
of the KP can affect the levels of tryptophan, thereby modulating
serotonin synthesis or causing suppression of cell proliferation.
In addition, the production of metabolites can provide a source
of nicotinamide dinucleotide (NAD+) and have other biologi-
cal effects, particularly in the immune, reproductive, and central
nervous systems. Depending on their expression pattern, TDO and
IDO enzymes may have similar or distinct biological activities.
Furthermore, in some organisms, gene duplication has resulted in
homologs of either TDO or IDO. In the case of IDO homologs,
there is evidence of functional divergence that has evolved in the
case of one of the duplicated genes.
EVOLUTION OF TDO
Tryptophan 2,3-dioxygenase is widely distributed across species,
from metazoans to bacteria, but has not been found in fungi.
Its enzymatic activity has been conserved consistently through-
out metazoan evolution (Yuasa and Ball, manuscript submitted).
A phylogenetic tree showing the distribution of TDO enzymes in
metazoan species is presented in Figure 2. Gene duplications have
resulted in some organisms possessing two TDO genes, e.g., Danio
rerio (zebrafish) and Stongylocentrotus purpuratus (sea urchin).
TDO is found in several hundred species/strains of bacteria. They
do not form a monophyletic group, and some bacterial TDOs
show sequence homology with eukaryotic TDOs. A few bacteria
have two TDO genes; however, they are located distant from each
other in the phylogenetic tree (Figure 2). This suggests that multi-
ple horizontal gene transfer events have occurred in bacterial TDO
evolution.
EVOLUTION OF IDO
Indoleamine 2,3-dioxygenase is also widely distributed from
bacteria to metazoans and, unlike TDO, can be found in fungi.
Gene duplication has occurred in a number of lineages to gener-
ate IDO homologs. For example, some Ascomycota fungi possess
IDOα, IDOβ, and IDOγ, while some Basidiomycota fungi have
IDOa, IDOb, and IDOc (5–7). A phylogenetic tree showing the
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FIGURE 1 | A conceptual diagram depicting the overlapping activities
of IDO andTDO enzymes and the distinct characteristics of some IDO
homologs.
distribution of IDO enzymes is presented in Figure 3. Mam-
mals also possess more than one IDO enzyme, namely, IDO1
and the more recently discovered IDO2 (8–10). Examining the
sequence divergence of the IDO1 and IDO2 proteins would sug-
gest a gene duplication event before the origin of the tetrapods
(8). However, the presence of two IDO homologs in mammals,
but only one IDO2-like enzyme in lower vertebrates, suggests
that the ancestral IDO2 gene was more recently duplicated,
before the rise of the mammals (10). Recently, IDO homologs,
one with higher homology to mammalian IDO1 compared to
IDO2, have been detected in a species of fish and turtle (Yuasa
et al., manuscript in preparation). We speculate that this indi-
cates that the duplication event was more ancient and that
the IDO1 gene has been lost in a number of lower vertebrate
lineages.
FUNCTIONAL CONVERGENCE OF IDO AND TDO
The genomic structures and sequences of the IDO and TDO genes
do not suggest a common ancestor, rather that the two genes have
FIGURE 2 | Phylogenetic relationships of knownTDOs constructed with
the maximum-likelihood method (unrooted tree). Multiple sequence
alignment at the amino acid level was generated using the MUSCLE program
(3) and the ML tree was constructed using MEGA 6 (4). The internal branch
labels are bootstrap values with 100 replications. D. rerio (D. rer ) and S.
purpuratus (S. pur ) have two TDOs. A few bacteria, Myxococcus xanthus (M.
xan), Ralstonia solanacearum GMI1000 (R. sal ), R. eutropha JMP134 (R. eut ),
and Xanthomonas campestris 33913 (X. cam), also have two TDOs. A
complete tree, with names of all species, is shown in Figure S1 in
Supplementary Material.
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FIGURE 3 | Phylogenetic relationships of known IDOs and IDO-related
proteins constructed with the maximum-likelihood method (unrooted
tree). Multiple sequence alignment at the amino acid level was generated
using the MUSCLE program (3) and the ML tree was constructed using
MEGA 6 (4). The internal branch labels are bootstrap values with 100
replications. The Medaka-fish, Oryzias latipes (O. lat ) and a soft-shelled turtle,
Pelodiscus sinensis (P. sin) have a putative IDO1. A complete tree, with names
of all species, is shown in Figure S2 in Supplementary Material.
evolved separately to catalyze the same reaction. Figure 4 depicts
amino acid homologies and genomic structures for some selected
TDO and IDO proteins and their homologs. Both enzymes are
heme-containing proteins and the crystal structures of human
IDO1 and bacterial TDOs have been obtained (11–13). IDO1 is
a monomeric enzyme while TDO is tetrameric with one heme
per monomer. Although there is low sequence identity between
the enzymes, the crystal structures reveal similarities in the heme-
binding environment and substrate-binding site (13). The step-
by-step process by which Trp is converted to N -formylkynurenine
by heme dioxygenases has been investigated over many years, and
the reaction mechanism is thought to be broadly similar between
the two enzymes (14).
Structurally-unrelated enzymes that catalyze the same reac-
tions have been termed analogous (rather than homologous)
enzymes. Examples of analogous enzymes are found in many
classes of enzymes, but are particularly clustered in those involved
in synthesis and hydrolysis of polysaccharides, effects of oxy-
gen on cell components, and synthesis/turnover of cell walls
(15). A suggested mechanism for the evolution of analogous
enzymes is that a changed substrate specificity or reaction mech-
anism results in the recruitment of an enzyme to perform a new
role (15). One difference between mammalian TDO and IDO
enzymes is the substrate selectivity; TDO is selective for the l-
Trp enantiomer, whereas IDO has a broader substrate range of
indole-containing compounds. IDO1 was originally isolated from
rabbit intestine as a d-Trp-catabolizing enzyme (16) and its sub-
strates include d- and l-Trp, tryptamine, 5-hydroxytryptophan,
and 5-hydroxytryptamine (17). The biological significance of the
oxidation of other substrates by IDO1 is not clear and the substrate
range of ancestral IDO enzymes is also unknown. We hypoth-
esize that ancestral IDO enzymes were broadly indole-oxidizing
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FIGURE 4 | Schematic representation of amino acid alignments for
selected IDO andTDO proteins. Amino acid contigs are shown as red (IDO)
or blue (TDO) boxes, and positions of introns indicated by thick vertical bars.
Gaps less than two amino acids in the alignments were omitted. Selected
sequences are from human beings, frog (Xenopus tropicalis), chicken (Gallus
gallus), zebrafish (Danio rerio), and abalone (Haliotis diversicolor ).
enzymes and mammalian IDO1 has evolved into an enzyme with
high affinity and efficiency for l-Trp as a substrate, with this
activity forming the basis of its biological actions.
It has been observed that analogous enzymes are more likely
to have a skewed phylogenetic distribution; for example, one iso-
form evolves in archaebacteria while the other is present in both
metazoan and bacteria (1). The absence of TDO enzymes in fungi
suggests that IDO enzymes are responsible for Trp metabolism
in this kingdom. In bacteria, some species possess TDO or IDO
enzymes and they occur exclusively to each other, suggesting that
only one is required for Trp metabolism (18). However, many
organisms, including all mammals, possess both TDO and IDO
and there is the potential for the enzymes to have overlapping
or distinct actions, depending upon their expression patterns.
For example, mammalian TDO is expressed in the liver and its
activity is upregulated by glucocorticoids and l-Trp (19, 20).
IDO1 has constitutive expression in some tissues, such as the
lung, but its expression can be widely induced by certain stim-
uli that are significant in immunity and inflammation, including
interferon-γ (IFNγ), lipopolysaccharide (LPS), and tumor necro-
sis factor (TNF) (21–23). IDO2 has constitutive expression in the
liver (8) and can be induced by cytokines in certain cell types
(9, 24, 25).
The following sections discuss some examples of IDO and
TDO having either overlapping or distinct biological effects based
on their common enzymatic activity and distinct expression
patterns, with a general focus on pathways and networks that
are significant in immunity and/or inflammation. The inter-
actions of KP metabolites with the aryl hydrocarbon receptor
(AhR) are described in more detail in other articles in this
issue. The roles of Trp-catabolizing enzymes in the placenta
and central nervous system also have been reviewed recently
(26, 27).
IMMUNE EVASION BY TUMORS
Expression of Trp-catabolizing enzymes, whether in cancer cells or
dendritic cells in tumor-draining lymph nodes,has been associated
with suppression of the effector T-cell responses toward tumors
and, hence, with a poorer prognosis. A number of pathways are
implicated [reviewed in Ref. (28)], including suppression of T-
cell proliferation through sensing of Trp depletion via the mTOR
and/or GCN2 kinase pathways; generation of Treg cells via either
the GCN2 kinase pathway and/or kynurenine (Kyn) activating
the AhR; and the pro-apoptotic properties of some KP metabo-
lites on T-cells. IDO1 expression, associated with these effects,
has been found in plasmacytoid dendritic cells (29) and human
tumors (30). Human IDO2 mRNA expression has been detected
in gastric, colon, and renal tumors (24) and mRNA/protein in
myeloid and plasmacytoid dendritic cells (31). TDO activity in
gliomas has been linked to activation of the AhR and reduced
antitumor immune responses (32). TDO expression also has been
found in a significant proportion of human tumors, and a TDO
inhibitor restored the ability of mice to reject TDO-expressing
tumors (33). While the relative importance of tumor versus den-
dritic cell expression is debatable, it is clear that there is the
potential for both IDO and TDO enzymes to be involved in
the suppression of immune responses toward tumors. Selective
inhibitors can distinguish the role of TDO and IDO enzymes, but
it is more difficult to define the role of IDO1 versus IDO2 using
pharmacological approaches despite some recent progress in that
direction (34). There is some confusion regarding the selectivity
and mode of action of the enantiomers of the most commonly
used IDO inhibitor, 1-methyl-tryptophan [reviewed in Ref. (35)],
so genetic approaches are also helpful for defining the function of
these enzymes; for example, an IDO inhibitor was ineffective at
preventing tolerance of transplanted melanoma in Ido1−/− mice,
suggesting that the inhibitor acted via IDO1 (36). These Ido1−/−
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mice recently have been found to express an enzymatically inac-
tive form of IDO2 in specific immune cell types (37), which should
be considered when drawing conclusions. However, silencing the
Ido1 gene by siRNA resulted in reduced tumor growth in B16F10
tumor-bearing mice (38). In addition, Ido2−/−mice did not repro-
duce the reduced susceptibility to inflammatory skin cancer seen in
the Ido1−/−mice (37). IDO2 activity may have a role in promoting
Treg generation (discussed in Treg Cells and Tolerance); however, it
appears that IDO1 is the homolog predominantly associated with
immune evasion by tumors. Selective inhibitors of TDO or IDO
enzymes have been proposed as adjunctive chemotherapies. The
IDO inhibitor 1-methyl-tryptophan can also act as Trp mimetic,
signaling amino acid sufficiency in the mTOR pathway (39). This
action has the potential to relieve some of the immune suppres-
sion caused by all three enzymes, thus modulation of downstream
pathways may provide broader efficacy as an adjunctive therapy
than would selectively targeting Trp-catabolizing enzymes.
Thus, the evidence for IDO1 modulating host–tumor cell inter-
actions is strong and diverse, but involvement of TDO and IDO2
is much less studied and requires further corroboration.
TREG CELLS AND TOLERANCE
The importance of the activation of the AhR by kynurenines in
the development of tolerance is reviewed in Ref. (40) and other
articles in this issue. Critical to the development of tolerance is the
generation and maintenance of Treg cells, with the kynurenine-
mediated activation of the AhR playing an important role (41). As
previously mentioned, TDO-mediated activation of the AhR has
been linked to reduced immune responses toward gliomas (32).
In addition, Tdo−/−mice had greater inflammatory responses and
mortality after LPS administration, similar to AhR−/− mice (42).
This suggests that the AhR is activated by kynurenines formed
by TDO in certain situations. The longer term development of
immune tolerance may depend on sustained kynurenine pro-
duction in particular microenvironments, such as dendritic cells.
Mice develop a tolerance to LPS, as they show reduced inflam-
matory responses and mortality on re-exposure. This tolerance
was observed to be dependent on the combined presence of IDO1
and the AhR, suggesting that IDO1 is important for the longer
term modulation of the immune response to LPS (42). This study
demonstrated a positive feedback loop where signaling through
the AhR induced IDO1 expression, which in turn produced sus-
tained activation of the AhR. This is similar to the transforming
growth factor β (TGF β)/IDO1 axis, in which a positive feed-
back loop results in sustained expression of IDO1, TGFβ, type
I interferons, and the generation of Treg cells [reviewed in Ref.
(40)]. Interestingly, the establishment of this axis is associated with
a non-enzymatic function of IDO1 (see Signaling Properties of
IDO1) (43). Kynurenine administration failed to restore tolerance
to LPS administration in Ido1−/− mice, suggesting that non-
enzymatic capabilities of IDO1 may also play a role in establishing
tolerance to endotoxins (42).
Many studies have identified IDO1 as the Trp-catabolizing
enzyme predominantly involved in the generation of Treg cells,
although we emphasize that the pharmacological approaches
employed in those studies would not distinguish between IDO1
and IDO2. For example, IDO inhibition with 1-methyl tryptophan
was shown to reduce Treg formation by CpG oligonucleotide-
stimulated human dendritic cells and in the lungs of Aspergillus
fumigatus-infected mice (44, 45). Other studies utilize the Ido1−/−
mouse; however, use of this strain is complicated by cell-specific
alternative-splicing leading to some loss of IDO2 activity (37).
Two studies employing both Ido1−/− and Ido2−/− mouse strains
showed that the formation of Treg cells either may be modulated
by IDO2 (37) or is specific to IDO1 activity (42), depending on the
model. In addition, siRNA knockdown of either IDO1 or IDO2 in
human dendritic cells reduced the formation of kynurenine and
Treg cells (31). The tolerance to LPS administration was specific
to IDO1 expression, as IDO2 deletion had no effects on outcomes
in either initial or subsequent administrations of LPS (42). The
generation of Treg cells in mice treated with CpG oligonucleotide
has been defined as IDO1 mediated (46), but the generation of
Treg cells was also reduced in Ido2−/− mice in this model (37).
In summary, all three Trp-catabolizing enzymes have the ability
to suppress immune responses. However, the longer term mainte-
nance of the Treg balance may require sustained expression in
particular microenvironments. This appears to occur in some
TDO- or IDO-expressing tumors and IDO-expressing dendritic
cells. It is noteworthy that IDO2 expression was found to be con-
stitutive in human myeloid and plasmacytoid dendritic cells, while
IDO1 showed a more restricted expression pattern, dependent
on prostaglandin E2 (31). Overall, we conclude that the different
expression patterns of the IDO proteins may determine whether
each is tolerogenic in response to specific stimuli.
NAD+ SUPPLY
NAD+ is an essential co-factor required by many biochemical
processes. It is formed either by a de novo synthesis pathway, from
metabolites of the KP, or via a salvage pathway using nicotinic
acid (NA) and nicotinamide (vitamin B3). Thus, a yeast strain
with its only Trp-catabolizing gene (BNA2, an IDO homolog)
deleted becomes a NA auxotroph. Expressing IDO/TDO enzymes
in this mutant strain will rescue the yeast if the enzyme has suffi-
cient Trp-catabolizing activity to provide a source of NAD+. Many
IDO enzymes do rescue the mutant strain, including mouse and
human IDO1 enzymes, IDOα/β enzymes from Pezizomycotina,
and IDOa/b enzymes from Agaricomycotina (7). As fungi do not
possess TDO, it is likely that IDO activity has a role in supplying
NAD+ in these microorganisms. NAD+ synthesis is not only deter-
mined by the activity of the Trp-catabolizing enzymes but also the
presence of all the downstream enzymes. One of these enzymes,
quinolinic acid phosphoribosyl-transferase, has been found to be
active only in the liver and kidney of rodents (47, 48). It has been
shown that the KP is the major route of NAD+ supply in rat
hepatocytes (49). Two Trp-catabolizing enzymes are constitutively
expressed in mouse liver – TDO and IDO2 (8, 19). TDO is most
likely to be involved in NAD+ supply since TDO enzymes, but
not IDO2 enzymes, were able to rescue the NA-auxotrophic yeast
strain [Yuasa and Ball, manuscript submitted (7)]. The lack of
significant activity of critical downstream enzymes for de novo
synthesis would suggest that most extrahepatic tissues rely on the
salvage pathway for NAD+ supply. Nevertheless, in vitro studies
on human brain cells have suggested that the KP pathway can
contribute to maintaining NAD+ and perhaps the distribution and
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activity of the enzymes in the pathway has not been fully elucidated
(50). In addition, while Tdo−/−mice showed significantly reduced
levels of circulating NAD+ when placed on a NA-deficient diet,
compared to a complete diet, they still maintained optimal rates
of growth (48). The amount of NAD+ in the liver was consistent in
wildtype and Tdo−/−mice fed either the complete or NA-deficient
diets. Measurements of metabolites in the urine showed that the
conversion rate of l-Trp to Kyn was increased in the Tdo−/− mice
on the NA-deficient diets. This suggests that extrahepatic IDO1
enzyme activity was increasing the circulating pool of Kyn, which
could then be further metabolized in the liver to synthesize NAD+
for recirculation to extrahepatic tissues. We may speculate that
IDO2 activity in the liver also contributes to maintaining the lev-
els of NAD+ in that tissue, in the absence of both NA in the diet
and TDO activity.
NAD+ supply also has modulatory effects in cancer and inflam-
mation. Inhibition of NAD+ formation has been proposed as a
chemotherapeutic target due to high rates of NAD+ consump-
tion by tumor cells. This is suggested to be predominantly due
to increased ADP-ribosylation from polyADP-ribose polymerase
activity (51). Although an inhibitor (FK866) of an enzyme in the
salvage pathway is efficacious as a chemotherapeutic agent (52),
little is known of the contribution of the de novo synthesis pathway
to tumor cell metabolism. NAD+ is also critical for mediating the
effects of sirtuins, some of which modulate inflammatory path-
ways. Again, the relative contributions of the de novo synthesis
pathway and the salvage pathways in sirtuin activation are unclear,
although an IDO inhibitor was shown to reduce both NAD+ lev-
els and sirtuin 1 activity in human primary astrocytes (53). It
should be noted that sirtuin 1 activity has been associated with
reduced Foxp3 stability and suppression of Treg cell formation
(54), in contrast to the Treg-promoting effects of the KP. In sum-
mary, while NAD+ supply regulates tumor cell metabolism and
inflammatory responses, the roles of the two supply pathways,
as well as each of the enzymes within them, still require eluci-
dation. We suggest that a focus on the KP–NAD+ axis in tumor
and immune cells would provide valuable information both to
clarify certain anomalies in the field and to determine whether it
is possible to interfere with this pathway in tumor cells without
compromising immune cell functions.
DIVERGENT EVOLUTION OF L-Trp-CATABOLIZING ENZYMES
TDO and IDO have evolved to have similar enzymatic functions,
and these enzymes coexist in most animals. In addition, gene
duplications have resulted in some species having more than one
homolog of each enzyme. For example, zebrafish have one IDO
enzyme and two TDO enzymes. The TDO enzymes are highly con-
served throughout vertebrate evolution (Table 1) and zebrafish
TDO paralogs have similar enzymatic activity and expression pat-
terns (Jusof et al., manuscript in preparation). IDO genes have
been duplicated independently in a number of lineages, for exam-
ple, IDO1 and IDO2 in mammals and IDOa, IDOb, and IDOc
in Agaricomycotina fungi. Compared with TDO enzymes, there
is lower sequence homology between both IDO paralogs and
orthologs (Table 1). The different biochemical and functional
properties observed among IDO enzymes is likely a result of the
greater sequence divergence. The following sections describe three
features found in certain IDO enzymes that are not shared among
all IDO enzymes.
LOW CATALYTIC-EFFICIENCY IDO ENZYMES
IDO enzymatic activity requires the reduction of the heme iron
from its ferric form to its ferrous form. Characterization of IDO
activity often begins by assessing the activity of the protein in a
reaction containing methylene blue (MB) as an electron source,
among other constituents including the substrate (55). IDO1
Table 1 | Amino acid identity over the aligned segments of IDO andTDO enzymes using blastp (http://blast.ncbi.nlm.nih.gov).
Human
IDO1 (%)
Human
IDO2 (%)
X. tropicalis
IDO (%)
G. gallus
IDO (%)
D. rerio
IDO (%)
H. diversicolor
IDO-like Mb (%)
Human IDO1 100 44 43 44 45 34
Human IDO2 44 100 53 60 50 37
X. tropicalis IDO 43 53 100 55 50 36
G. gallus IDO 44 60 55 100 55 38
D. rerio IDO 45 50 50 55 100 36
H. diversicolor IDO-like Mb 34 37 36 38 36 100
Human
TDO (%)
X. tropicalis
TDO (%)
G. gallus
TDO (%)
D. rerio
TDOa (%)
D. rerio
TDOb (%)
Human TDO 100 82 84 75 75
X. tropicalis TDO 82 100 86 77 78
G. gallus TDO 84 86 100 77 76
D. rerio TDOa 75 77 77 100 76
D. rerio TDOb 75 78 76 76 100
No significant similarity (E value<1) was observed when aligning the TDO proteins with IDO proteins. Selected sequences are from human beings, frogs (Xenopus
tropicalis), chickens (Gallus gallus), zebrafish (Danio rerio), and abalone (Haliotis diversicolor).
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enzymes are highly efficient at metabolizing Trp in the MB assay. In
contrast, IDO2 enzymes have a much higher K m and lower V max
for Trp in this reaction (10, 56–58). The physiological reductant
of IDO enzymes originally was proposed to be superoxide anion
(59) and more recently suggested to be cytochrome b5 (60, 61).
Human IDO1 showed reduced activity in a reaction containing
cytochrome b5 compared with the MB assay (61). In contrast, the
Trp-catalyzing efficiency of mouse IDO2 was greatly improved in
the cytochrome b5 reaction, although it was still significantly less
efficient than mouse IDO1 (56). The dependence of enzymatic
activity on co-factors underscores the difficulty in assessing the
biochemical characteristics of IDO homologs. It is certainly possi-
ble that the optimal reaction system to observe IDO2 activity has
not been developed. Despite this limitation, several other lines of
evidence suggest that IDO2 enzymes have lower Trp-metabolizing
activity than the IDO1 counterparts. First, the amount of Kyn
formed in mammalian cells transfected with mouse IDO2 is lower
than in cells transfected with mouse IDO1 (8, 9). In addition,
human IDO2 expression produced significantly less Kyn than
mouse IDO2 (9, 62). Second, expression of IDO1, but not mouse
or human IDO2, rescued a NA-auxotrophic yeast strain (7). This
suggests that IDO2 enzymes do not possess sufficient activity to
supply the metabolites required for NAD+ supply in yeast. On the
other hand, knockdown of human IDO2 expression in dendritic
cells by siRNA significantly suppressed Kyn formation and this
was associated with decreased generation of Treg cells (31). Thus,
IDO2 may have sufficient enzymatic activity to generate a biologi-
cal effect in certain systems. The constitutive expression of IDO2 in
subsets of dendritic cells, compared with the regulated expression
of IDO1, may be an example where the weak enzymatic activity of
IDO2 is still able to produce a distinct biological effect, compared
with IDO1, by virtue of its unique expression pattern (31).
Ido2−/− mice, while having unaltered plasma Kyn levels, show
reduced skin contact hypersensitivity responses and attenuated
Treg cell generation (37). In addition, Ido2−/− mice have selec-
tively less autoantibody production, compared with overall anti-
body production, leading to reduced joint inflammation in a
spontaneous model of arthritis (63). Interestingly, the effect was
unrelated to serum Kyn levels, because these were unchanged
in Ido2 −/− mice while Ido1 −/− mice had reduced circulat-
ing Kyn but no attenuation of joint inflammation. Furthermore,
while 1-methyl-tryptophan could inhibit Kyn formation in IDO2-
expressing HEK293T cells, it did not affect IDO2-mediated sup-
pression of T-cell proliferation in co-culture experiments (62).
Taken together, these findings may point to some effects of IDO2
being mediated via a mechanism unrelated to Trp metabolism/Kyn
formation, although, in the mouse model, it is possible that
localized enzymatic activity is sufficient to produce the effect.
Interestingly, other lineages outside the metazoan kingdom
have independently generated IDO homologs through gene dupli-
cation events. Some of these IDO homologs have very low catalytic
activities, similar to IDO2 enzymes, as tested in the MB assay (5, 6,
18). The low enzymatic activity of these homologs was confirmed
by the lack of rescue of the NA-auxotrophic yeast strain (7). These
low catalytic-efficiency enzymes include IDOγ in Perzizomycotina
and IDOc in Basidiomycota. The role of the low catalytic-efficiency
IDOs in Trp metabolism, or another metabolic process, is not
well understood. l-Trp is metabolized by both IDO1 and IDO2
enzymes; however, assessing tryptophan derivatives has revealed
substrates, such as 5-methoxytryptophan, which are metabolized
by human IDO2, but not human IDO1 (58). Human IDO2 has a
higher affinity for some of these substrates than for l-Trp. Addi-
tionally, we found that Trp metabolism by mouse IDO2 could
be inhibited by a much wider range of compounds compared
with mouse IDO1 (34). We conclude that IDO2 enzymes interact
with a different, but overlapping, range of substrates/inhibitors
compared to IDO1 enzymes.
Recent studies show that IDO1 enzymes can possess heme
peroxidase and indole peroxygenase activity in the presence of
hydrogen peroxide and relevant substrates (64, 65). These activ-
ities have yet to be investigated in other IDO enzymes’ par-
alogs/orthologs. The biological significance of these alternative
reactions is unknown. However, as IDO enzymes with relatively
low efficiency at converting Trp to Kyn have been maintained in
several lineages during evolution, we believe that it would be of
interest to investigate whether these enzymes catalyze these alter-
native reactions more efficiently than the conversion of Trp to
N -formylkynurenine.
Lymphocytes appeared early in vertebrate evolution, with the
emergence of jawed fish, and the adaptive immune system has
become increasingly complex as vertebrates have evolved through
to mammals. Another feature of mammalian evolution is the
development of the chorion into the larger, more complex pla-
centa. We speculate that the development of these two systems has
favored acquisition of high Trp-catabolizing efficiency in IDO1
enzymes in order to fulfill particular biological roles. Fungi do
not have TDO and it may be that high Trp-catabolizing efficiency
IDO enzymes, IDOα/β and IDOa/b, have evolved in fungi to pro-
vide a source of NAD+. The occurrence and conservation of IDO
enzymes with lower catalytic activity for Trp metabolism in dif-
ferent kingdoms suggests that these enzymes are still fulfilling a
role, albeit one that is less well understood. We conjecture that
potential roles may include Trp metabolism in particular microen-
vironments, or metabolism of other substrates including through
an alternative oxidation reaction.
SIGNALING PROPERTIES OF IDO1
It was shown that IDO1 expression, but not IDO1 catalytic activity,
was necessary for the immunoregulatory effects leading to longer
term self-tolerance of plasmacytoid dendritic cells treated with
TGF-β (43). Immunoreceptor tyrosine-based inhibitory motifs
(ITIMs) were phosphorylated in mouse IDO1 in response to TGF-
β. This was followed by upregulation and recruitment of tyrosine
phosphatases, SHP-1 and SHP-2, and the initiation of a cascade of
downstream events favoring activation of the non-canonical NF-
κB pathway, leading to the sustained expression of IDO1, TGF-β,
and interferon-α. Two ITIMs (ITIM1 and ITIM2) were observed
to be present in an alignment of human being, rat, dog, and mouse
IDO1 proteins. In contrast, a tyrosine to phenylalanine substitu-
tion in IDO2 proteins meant that only ITIM2 was present. The
presence of only one ITIM was shown to prevent the recruitment
of the phosphatase, so that mouse IDO2 does not possess the same
signaling capability as mouse IDO1. In addition, the ITIM motifs
were demonstrated to regulate the SOCS3-dependent degradation
www.frontiersin.org October 2014 | Volume 5 | Article 485 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ball et al. Evolution of tryptophan-catabolizing enzymes
of the IDO1 protein in response to other cytokines, thus possess-
ing both these motifs also provides an additional mechanism for
regulating IDO1 protein turnover (66). The expression of human
IDO2 in dendritic cells was found to be SOCS3-independent, cor-
relating with its lack of two ITIM motifs (31). Thus, sequence
differences in the IDO1 and IDO2 proteins have resulted in an
additional signaling function and mechanism of regulation for
one of the homologs.
There is some evidence that IDO2 acts through effector path-
ways independent of enzymatic activity. As discussed earlier, the
attenuation in joint inflammation in Ido2−/− mice was unrelated
to circulating Kyn levels and an inhibitor of IDO2-catalyzed Kyn
formation did not relieve IDO2-mediated suppression of T-cell
proliferation (62, 63). Trp depletion induces translation of the liver
inhibitory protein via the GCN2 kinase pathway, and this could be
reversed by Trp supplementation in IDO1-expressing cells but not
in IDO2-expressing cells (9). We suggest that these findings imply
that potential alternative signaling properties of IDO2 should be
investigated.
IDO-LIKE MYGLOBIN
Hemoglobins and myoglobins from bacteria, plants, and ani-
mals are thought to have evolved from a common ancestral gene
encoding a 14–16 kDa protein [reviewed in Ref. (67)]. A myo-
globin isolated from the abalone H. diversicolor, however, was a
39 kDa protein quite different to previous myoglobin proteins and
with significant homology to the IDO family of enzymes (68).
The IDO reaction mechanism involves the formation of an oxy-
genated intermediate with an absorption spectrum similar to that
of oxymyoglobin (69). IDO enzymes do not act as oxygen carriers
as this intermediate is unstable. The IDO-like myoglobin possibly
may have evolved to reversibly bind oxygen through amino acid
changes in the heme-binding cavity (67). IDO-like myoglobins are
found in several families in the Vetigastropoda and, interestingly,
the conventional myoglobin is not present in these families (67).
Thus, in an example of functional convergence with the myo-
globin family, the IDO-like myoglobins have evolved to fulfill the
function of an oxygen carrier where conventional myoglobins have
been lost. However, as an example of functional divergence, IDO-
like myoglobins have lost the ability to metabolize tryptophan and
to function as an IDO enzyme (Yuasa and Ball, manuscript in
preparation).
SUMMARY
Convergent evolution usually occurs by two different proteins
evolving to fill the same biological role in different organisms.
For example, TDO is likely to be the enzyme mostly responsible
for Trp metabolism leading to NAD+ supply in mammals; how-
ever, its absence in fungi suggests that IDO enzymes perform this
function in fungi. However, both TDO and IDO enzymes, with
Trp-catabolizing activity, are present in vertebrates. The functional
evolution of IDO proteins is more complex than TDO evolution
as efficient Trp-catabolizing activity is not uniformly conserved.
Mammalian IDO1s have evolved to be highly efficient at catab-
olizing Trp. It is possible that the increasing complexity of the
vertebrate immune and reproductive systems might have led to
selective pressures favoring the acquisition of Trp-catabolizing
activity, in particular tissues or situations. Although Trp catab-
olism, by either IDO or TDO, may have similar effects in some cell
types, e.g., tumors, Trp catabolism in dendritic cells that drives
tolerance may be an IDO-mediated effect.
Gene duplication is a driving force in evolution as it allows
one gene to perform its original function while another, under
less selective pressure, may diverge and develop new characteris-
tics and/or lose its original ones. Both IDO and TDO genes have
undergone duplications in some lineages, although IDO proteins
show much greater sequence divergence than TDO proteins. This
has led to greater diversity within the IDO family, with differing
enzymatic activities and signaling capabilities. For example, IDO1
enzymes, but not IDO2 enzymes, possess two motifs that confer a
signaling role on the proteins, regulating both expression and sta-
bility. Thus, the sequence diversity among IDO proteins leads to
a distinct mechanism for sustaining IDO1 expression in dendritic
cells and the development of tolerance, in response to specific
stimuli. The diverse characteristics and different expression pat-
terns of the Trp-catabolizing enzymes equate to distinct biological
roles for the enzymes.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at
http://www.frontiersin.org/Journal/10.3389/fimmu.2014.00485/
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